André Ostachkov

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016.

Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016.

Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.